[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355056-105":59,"doc-detail-355056-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cryb2-is-a-biomarker-for-poor-prognosis-and-response-to-cdk46-inhibitors-in-breast-cancer","CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer","","Breast cancer mortality is higher in African American women than in European American women, while molecular drivers and actionable predictors remain insufficiently defined. Prior work linked β-crystallin B2 (CRYβB2) to African American tumor upregulation and oncogenesis via nucleolin (NCL). This study shows CRYβB2 overexpression activates cell-cycle and CDK4/6 signaling across multiple breast cancer models, and that disrupting CRYβB2 or NCL shifts sensitivity to the CDK4/6 inhibitor palbociclib, with CRYβB2 levels inversely relating to IC50 values.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cryb2-is-a-biomarker-for-poor-prognosis-and-response-to-cdk46-inhibitors-in-breast-cancer/355056/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cryb2-is-a-biomarker-for-poor-prognosis-and-response-to-cdk46-inhibitors-in-breast-cancer/355056.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is CRYβB2 in the context of this study?","Question",{"text":113,"@type":114},"CRYβB2 (β-crystallin B2) is described as a molecule upregulated in African American breast tumors and investigated here as a driver of cell-cycle progression through CDK4/6 pathway activation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does CRYβB2 relate to response to CDK4/6 inhibitors?",{"text":118,"@type":114},"CRYβB2 overexpression increases sensitivity to palbociclib, with CRYβB2 expression inversely correlating with IC50, while CRYβB2 knockdown confers resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"What role does nucleolin (NCL) play alongside CRYβB2?",{"text":122,"@type":114},"Nucleolin is positioned as a functional mediator of CRYβB2-driven oncogenesis; targeting NCL by knockout or using the NCL aptamer AS-1411 alters levels of CDK4 pathway markers and modulates palbociclib sensitivity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355056,1790359582,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Yan et al. Breast Cancer Research (2026) 28:42 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02188-2](https://doi.org/10.1186/s13058-025-02188-2)  \nRESEARCH Open Access  \nCRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer  \nYu Yan1,2, Athira Narayan1, Marzieh Mazinani1, Harumi Saeki3,4, Tao Huang2, Gabi Lofland 1, Edward Gabrielson4, Leslie Cope5, Yasmine M. Kanaan6, Ali Afsari7, Tammey Naab8, Saraswati Sukumar5, Martin G. Pomper 1,5,9,11* and Vanessa F. Merino 1,10*  \nAbstract  \nBreast cancer mortality is higher in African American (AA) women than in European American women, but the molecular mechanisms remain poorly understood. Previously, we showed that β-crystallin B2 (CRYβB2) is upregulated in AA breast tumors and promotes oncogenesis via nucleolin (NCL) activation. Presently no biomarkers, other than estrogen receptor (ER)/progesterone receptor (PR) expression, are used to prescribe cyclindependent kinases 4/6 inhibitors (CDK4/6i) for women with hormone receptor positive (HR+) metastatic breast cancer. Here, we show that CRYβB2 overexpression drives cell cycle progression and CDK4/6 pathway activation in premalignant, ductal carcinoma in situ (DCIS), triple-negative breast cancer (TNBC), and ER⁺ breast cancer models. Targeting CRYβB2 or NCL reduced CDK4, cell division cycle 25 A (Cdc25a), and phosphorylated Rb (ppRb) levels. Tumors expressing CRYβB2 were selectively sensitive to the CDK4/6 inhibitor palbociclib, with CRYβB2 expression inversely correlating with IC₅₀ values. Knockdown of CRYβB2 conferred resistance, whereas NCL knockout or treatment with the NCL aptamer AS-1411 sensitized cells to palbociclib. In TNBC and ER+ tumors of AA patients, high CRYβB2 expression correlated with CDK4/pRb activation and decreased survival in TNBC. These results indicate that CRYβB2 drives CDK4/6 activation and may serve as a prognostic biomarker and predictor of response topalbociclib therapy.  \nKeywords European American, African American, CRYβB2, Nucleolin, CDK4, pRb, Palbociclib  \n*Correspondence:  \nMartin G. Pomper [martin.pomper@utsouthwestern.edu](martin.pomper@utsouthwestern.edu)[ ](martin.pomper@utsouthwestern.edu)Vanessa F. Merino [vmerino1@umd.edu](vmerino1@umd.edu)  \n1Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n2Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  \n3Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n4Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n5Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n6Department of Microbiology, College of Medicine, Howard University, Washington, DC, USA  \n7Department of Pathology, College of Medicine, Howard University, Washington, DC, USA  \n8Athari BioSciences, Sterling, VA, USA  \n9Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n10Present address: University of Maryland, Baltimore, MD, USA  \n11Present address: University of Texas Southwestern Medical Center, Dallas, TX, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated ","cbCaiiKtPHLLqHfr","https://ap.wps.com/l/cbCaiiKtPHLLqHfr","pdf",5862982,11,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is CRYβB2 in the context of this study?\",\"answer\":\"CRYβB2 (β-crystallin B2) is described as a molecule upregulated in African American breast tumors and investigated here as a driver of cell-cycle progression through CDK4/6 pathway activation.\"},{\"question\":\"How does CRYβB2 relate to response to CDK4/6 inhibitors?\",\"answer\":\"CRYβB2 overexpression increases sensitivity to palbociclib, with CRYβB2 expression inversely correlating with IC50, while CRYβB2 knockdown confers resistance.\"},{\"question\":\"What role does nucleolin (NCL) play alongside CRYβB2?\",\"answer\":\"Nucleolin is positioned as a functional mediator of CRYβB2-driven oncogenesis; targeting NCL by knockout or using the NCL aptamer AS-1411 alters levels of CDK4 pathway markers and modulates palbociclib sensitivity.\"}]","CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer | PDF",1790115638,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41312a2292a2d289ee280d2d752dfe62.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/323fe6472198012797025c2763baff20.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25c0ee58fbbf1170cdae70e3eef5b824.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38046f39644c7edd38eb95311fa07587.webp",980,1306]